AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18212498 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iron sucrose (Venofer(R), 100 mg iron, twice a week for 8 weeks, then once a week for another 4 weeks)
Number of subjects: 136
Study 18212498 — intervention group
Group type: COMPARATOR
Intervention: Oral ferrous succinate (200 mg t.i.d. for 12 weeks)
Number of subjects: 136
Study 16314019 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep Deprivation
Number of subjects: 12
Study 14572429 — intervention group
Group type: EXPERIMENTAL
Intervention: Outreach intervention (tailored letters and motivational telephone interviews)
Number of subjects: 501
Study 14572429 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 501
Study 10735703 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-bonded CPB
Number of subjects: 34
Study 10735703 — intervention group
Group type: COMPARATOR
Intervention: Non-heparin-bonded CPB
Number of subjects: 34
Study 9187454 — intervention group
Group type: EXPERIMENTAL
Intervention: Scrubbing for three minutes
Number of subjects: 25
Study 9187454 — intervention group
Group type: COMPARATOR
Intervention: Scrubbing for two minutes
Number of subjects: 25
Study 1286498 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil (mean dose, 0.76 mg)
Number of subjects: 197
Study 1286498 — intervention group
Group type: COMPARATOR
Intervention: Placebo (mean dose, 8.9 ml)
Number of subjects: 197
Study 1286498 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 197
Study 1286498 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 197
Study 3994880 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane
Number of subjects: 60
Study 3994880 — intervention group
Group type: EXPERIMENTAL
Intervention: Enflurane
Number of subjects: 60
Study 3994880 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 60
Study 31627715 — intervention group
Group type: EXPERIMENTAL
Intervention: Massive Haemorrhage protocol including systematic early administration of tranexamic acid (TXA)
Number of subjects: 116
Study 31627715 — intervention group
Group type: COMPARATOR
Intervention: Standard care before the implementation of the Massive Haemorrhage protocol
Number of subjects: 116
Study 30100374 — intervention group
Group type: EXPERIMENTAL
Intervention: CIK cell infusion
Number of subjects: 6
Study 27434703 — intervention group
Group type: EXPERIMENTAL
Intervention: Tennis-serving protocol until the onset of fatigue (defined as a rating of 15 on the Borg Scale and reaching a heart rate of 70% of maximum)
Number of subjects: 20
Study 27434703 — intervention group
Group type: COMPARATOR
Intervention: Rest (control group)
Number of subjects: 20
Study 25409678 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrate 4% catheter lock solution
Number of subjects: 0
Study 25409678 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin at a concentration of 5,000 IU/mL
Number of subjects: 0
Study 22124453 — intervention group
Group type: EXPERIMENTAL
Intervention: Fabuless (structured lipid emulsion)
Number of subjects: 24
Study 22124453 — intervention group
Group type: COMPARATOR
Intervention: Control fat
Number of subjects: 24
Study 21066885 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment group (CTG) with Shenmai Injection (SMI) and enteral nutrition
Number of subjects: 58
Study 21066885 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment group (CTG)
Number of subjects: 58
Study 17885694 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal oxygen therapy
Number of subjects: 543
Study 17885694 — intervention group
Group type: COMPARATOR
Intervention: Room air breathing
Number of subjects: 543
Study 15613582 — intervention group
Group type: EXPERIMENTAL
Intervention: DTO and phenobarbital
Number of subjects: 32
Study 15613582 — intervention group
Group type: COMPARATOR
Intervention: DTO alone
Number of subjects: 32
Study 12163718 — intervention group
Group type: EXPERIMENTAL
Intervention: Allograft bone (fresh-frozen femoral head)
Number of subjects: 69
Study 12163718 — intervention group
Group type: COMPARATOR
Intervention: Autograft bone (harvested from the iliac crest)
Number of subjects: 69
Study 9894538 — intervention group
Group type: COMPARATOR
Intervention: Cage rearing system
Number of subjects: 34
Study 9894538 — intervention group
Group type: EXPERIMENTAL
Intervention: Cage-less system with young hens and fresh bedding material
Number of subjects: 34
Study 9894538 — intervention group
Group type: EXPERIMENTAL
Intervention: Cage-less system with older hens and old bedding material
Number of subjects: 34
Study 7788195 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 ml of saline
Number of subjects: 300
Study 7788195 — intervention group
Group type: COMPARATOR
Intervention: 5 ml of saline
Number of subjects: 300
Study 7788195 — intervention group
Group type: COMPARATOR
Intervention: No saline
Number of subjects: 300
Study 2220578 — intervention group
Group type: EXPERIMENTAL
Intervention: Bepridil (300 to 500 mg/day)
Number of subjects: 87
Study 2220578 — intervention group
Group type: COMPARATOR
Intervention: Diltiazem (180 to 300 mg/day)
Number of subjects: 87
Study 300825 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic antibiotics before and after the operation
Number of subjects: 904
Study 300825 — intervention group
Group type: COMPARATOR
Intervention: No prophylactic systemic antibiotics
Number of subjects: 904
Study 31286172 — intervention group
Group type: COMPARATOR
Intervention: Arm cycling (ARM)
Number of subjects: 14
Study 31286172 — intervention group
Group type: COMPARATOR
Intervention: Leg cycling (LEG)
Number of subjects: 14
Study 31286172 — intervention group
Group type: COMPARATOR
Intervention: Arm and leg cycling (A&L)
Number of subjects: 14
Study 31286172 — intervention group
Group type: COMPARATOR
Intervention: Quiet sitting (CTRL)
Number of subjects: 14
Study 28108978 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-course intravenous levofloxacin (750 mg/day for 5 days)
Number of subjects: 317
Study 28108978 — intervention group
Group type: COMPARATOR
Intervention: Conventional intravenous/oral levofloxacin (500 mg/day for 7-14 days)
Number of subjects: 317
Study 28108978 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-course intravenous levofloxacin (750 mg/day)
Number of subjects: 317
Study 28108978 — intervention group
Group type: COMPARATOR
Intervention: Conventional intravenous/oral levofloxacin (500 mg/day)
Number of subjects: 317
Study 25040296 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed dye laser (PDL) treatment (wavelength 595 nm; fluence 8 J cm(‐2); pulse duration 0.5 ms; spot size 10 mm)
Number of subjects: 39
Study 25040296 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 39
Study 25040296 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed dye laser (PDL) treatment
Number of subjects: 39
Study 24035402 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted cognitive remediation therapy (CACR)
Number of subjects: 67
Study 24035402 — intervention group
Group type: COMPARATOR
Intervention: Active control condition
Number of subjects: 67
Study 20427547 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidimensional Family Therapy-Detention to Community (MDFT-DTC)
Number of subjects: 0
Study 20427547 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 19928509 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine (IVL) 3 mg x kg(‐1) for 30 min
Number of subjects: 43
Study 19928509 — intervention group
Group type: COMPARATOR
Intervention: Saline 100 ml for 30 min
Number of subjects: 43
Study 17703241 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide-formoterol as maintenance and reliever treatment
Number of subjects: 2143
Study 17703241 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol-fluticasone as maintenance medication plus salbutamol as needed
Number of subjects: 2143
Study 14718489 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular testosterone (200 mg every 3 weeks)
Number of subjects: 11
Study 14718489 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 12761015 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-mL volume of epidural fentanyl
Number of subjects: 60
Study 12761015 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-mL volume of epidural fentanyl
Number of subjects: 60
Study 12761015 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-mL volume of epidural fentanyl
Number of subjects: 60
Study 12761015 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (2-mL, 10-mL, 20-mL)
Number of subjects: 60
Study 10465993 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol dependent patients with respiratory symptoms (Group I)
Number of subjects: 124
Study 10465993 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol dependent patients without respiratory symptoms (Group II)
Number of subjects: 124
Study 10465993 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (Control group)
Number of subjects: 124
Study 7782978 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive oral hygiene training program with detailed information, self-diagnosis training, and ongoing motivation.
Number of subjects: 227
Study 7782978 — intervention group
Group type: EXPERIMENTAL
Intervention: Shorter oral hygiene training program without motivation and feedback.
Number of subjects: 227
Study 7782978 — intervention group
Group type: COMPARATOR
Intervention: Control group with no motivation sessions or oral hygiene training.
Number of subjects: 227
Study 2194971 — intervention group
Group type: EXPERIMENTAL
Intervention: pivampicillin/pivmecillinam
Number of subjects: 36
Study 2194971 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 36
Study 488428 — intervention group
Group type: COMPARATOR
Intervention: 50 mg progesterone injection
Number of subjects: 0
Study 31182338 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg/day
Number of subjects: 38
Study 31182338 — intervention group
Group type: EXPERIMENTAL
Intervention: Glimepiride 2 mg/day
Number of subjects: 38
Study 31182338 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 28739319 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary advice pamphlet
Number of subjects: 70
Study 28739319 — intervention group
Group type: COMPARATOR
Intervention: Care and maintenance advice for dentures
Number of subjects: 70
Study 24845394 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg of transdermal testosterone cream (TTC)
Number of subjects: 7
Study 24845394 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of transdermal testosterone cream (TTC)
Number of subjects: 7
Study 23623952 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive Psychotherapy (PPT) group (n=16)
Number of subjects: 34
Study 23623952 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=18)
Number of subjects: 34
Study 22171999 — intervention group
Group type: COMPARATOR
Intervention: Essential oil mouthwash with alcohol (control)
Number of subjects: 30
Study 22171999 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential oil mouthwash without alcohol (test)
Number of subjects: 30
Study 19443520 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry powder inhalers (DPIs)
Number of subjects: 15
Study 17441983 — intervention group
Group type: EXPERIMENTAL
Intervention: Astra Tech Single Tooth Implant (ST) with Microthread
Number of subjects: 17
Study 17441983 — intervention group
Group type: COMPARATOR
Intervention: Astra Tech TiOblast Implant (TB) without Microthread
Number of subjects: 17
Study 15197140 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide (1.5 to 12 mg/d)
Number of subjects: 175
Study 15197140 — intervention group
Group type: COMPARATOR
Intervention: Glyburide (5 to 20 mg/d)
Number of subjects: 175
Study 15197140 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide
Number of subjects: 175
Study 15197140 — intervention group
Group type: COMPARATOR
Intervention: Glyburide
Number of subjects: 175
Study 11443622 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemoradiotherapy with cisplatin (60 mg/m(2) on Days 1 and 22) and etoposide (100 mg/m(2) on Days 1, 2, 3, 22, 23, 24) plus 5940 cGy radiation in 180-cGy fractions over 6 weeks
Number of subjects: 42
Study 11443622 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemoradiotherapy with surgical resection
Number of subjects: 42
Study 9514312 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (0.75 g/kg)
Number of subjects: 8
Study 9514312 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 8064994 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocaloric (HC) feeding (50% resting metabolic energy expenditure, plus protein; calories:nitrogen = 75:1)
Number of subjects: 16
Study 8064994 — intervention group
Group type: COMPARATOR
Intervention: Control (C) feeding (100% resting metabolic energy expenditure, plus protein; calories:nitrogen = 150:1)
Number of subjects: 16
Study 31498370 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertensive patients
Number of subjects: 52
Study 31342445 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathways Early ASD Intervention (n=32)
Number of subjects: 56
Study 31342445 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU) (n=24)
Number of subjects: 56
Study 28835597 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% casein phosphopeptide‐amorphous calcium phosphate (CPP‐ACP) paste applied twice a day for 36 months
Number of subjects: 41
Study 28835597 — intervention group
Group type: COMPARATOR
Intervention: Fluoridated toothpaste applied twice a day for 36 months
Number of subjects: 41
Study 26563906 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week exercise intervention consisting of three one-hour low-intensity outdoor running sessions a week
Number of subjects: 108
Study 26563906 — intervention group
Group type: COMPARATOR
Intervention: Wait list (control)
Number of subjects: 108
Study 23288297 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline-based care
Number of subjects: 523
Study 23288297 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 523
Study 20096957 — intervention group
Group type: EXPERIMENTAL
Intervention: CBP gene variants (intron 4CT and intron 3AC polymorphisms)
Number of subjects: 5804
Study 20096957 — intervention group
Group type: EXPERIMENTAL
Intervention: Haplotype with variant alleles of intron 4CT and intron 3AC polymorphisms
Number of subjects: 5804
Study 18393298 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of lofexidine hydrochloride (1.2 mg and 2.0 mg)
Number of subjects: 0
Study 18393298 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidose of lofexidine hydrochloride (0.4 mg)
Number of subjects: 0
Study 18393298 — intervention group
Group type: COMPARATOR
Intervention: Single dose of lofexidine hydrochloride (1.2 mg)
Number of subjects: 0
Study 18393298 — intervention group
Group type: COMPARATOR
Intervention: Single dose of lofexidine hydrochloride (2.0 mg)
Number of subjects: 0
Study 16618360 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma-linolenic acid (GLA) supplementation
Number of subjects: 131
Study 16618360 — intervention group
Group type: COMPARATOR
Intervention: Placebo (non-supplemented group)
Number of subjects: 131
Study 15181099 — intervention group
Group type: EXPERIMENTAL
Intervention: Acylated ghrelin (AG) 1.0 microg/kg i.v.
Number of subjects: 6
Study 15181099 — intervention group
Group type: EXPERIMENTAL
Intervention: Unacylated ghrelin (UAG) alone
Number of subjects: 6
Study 15181099 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-administration of UAG and AG
Number of subjects: 6
Study 11107710 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclopirox 8% nail lacquer
Number of subjects: 0
Study 11107710 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vehicle control)
Number of subjects: 0
Study 11107710 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclopirox 8% nail lacquer (meta-analysis)
Number of subjects: 0
Study 9288642 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved stereological technique for estimating volumes of structures in three-dimensional arrays
Number of subjects: 0
Study 8347054 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine 600 mg/day
Number of subjects: 14
Study 3538486 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate 200 micrograms twice daily
Number of subjects: 31
Study 3538486 — intervention group
Group type: COMPARATOR
Intervention: Beclomethasone dipropionate 100 micrograms four times daily
Number of subjects: 31
Study 29716611 — intervention group
Group type: EXPERIMENTAL
Intervention: Video assisted learning plus a nodal point operation primer (Group B)
Number of subjects: 45
Study 29716611 — intervention group
Group type: COMPARATOR
Intervention: Video assisted learning (Group A)
Number of subjects: 45
Study 26927662 — intervention group
Group type: EXPERIMENTAL
Intervention: CIMAvax-EGF vaccine
Number of subjects: 405
Study 26927662 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care
Number of subjects: 405
Study 26927662 — intervention group
Group type: EXPERIMENTAL
Intervention: CIMAvax-EGF vaccine (per-protocol setting)
Number of subjects: 405
Study 26927662 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care (per-protocol setting)
Number of subjects: 405
Study 26927662 — intervention group
Group type: EXPERIMENTAL
Intervention: CIMAvax-EGF vaccine (high EGF concentration at baseline)
Number of subjects: 405
Study 24360369 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafenoquine 50 mg plus chloroquine
Number of subjects: 329
Study 24360369 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafenoquine 100 mg plus chloroquine
Number of subjects: 329
Study 24360369 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafenoquine 300 mg plus chloroquine
Number of subjects: 329
Study 24360369 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafenoquine 600 mg plus chloroquine
Number of subjects: 329
Study 24360369 — intervention group
Group type: EXPERIMENTAL
Intervention: Primaquine 15 mg for 14 days plus chloroquine
Number of subjects: 329
Study 24360369 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine alone
Number of subjects: 329
Study 24360369 — intervention group
Group type: COMPARATOR
Intervention: Tafenoquine 300 mg vs Chloroquine alone
Number of subjects: 329
Study 24360369 — intervention group
Group type: COMPARATOR
Intervention: Tafenoquine 600 mg vs Chloroquine alone
Number of subjects: 329
Study 24360369 — intervention group
Group type: COMPARATOR
Intervention: Primaquine vs Chloroquine alone
Number of subjects: 329
Study 22665535 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin and vincristine (CV)
Number of subjects: 274
Study 22665535 — intervention group
Group type: EXPERIMENTAL
Intervention: Thioguanine, procarbazine, lomustine, and vincristine (TPCV)
Number of subjects: 274
Study 22665535 — intervention group
Group type: COMPARATOR
Intervention: Both regimens (CV and TPCV)
Number of subjects: 274
Study 21121823 — intervention group
Group type: EXPERIMENTAL
Intervention: Researcher access to eligible participants
Number of subjects: 0
Study 21121823 — intervention group
Group type: EXPERIMENTAL
Intervention: Organisational culture and attitudes of service providers
Number of subjects: 0
Study 21121823 — intervention group
Group type: EXPERIMENTAL
Intervention: Development of collaborative partnerships between research and clinical communities
Number of subjects: 0
Study 18696358 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (1.5 g)
Number of subjects: 708
Study 16038370 — intervention group
Group type: EXPERIMENTAL
Intervention: Nafarelin
Number of subjects: 59
Study 16038370 — intervention group
Group type: COMPARATOR
Intervention: Danazol
Number of subjects: 59
Study 12061359 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous gastric drip (CGD)
Number of subjects: 58
Study 12061359 — intervention group
Group type: COMPARATOR
Intervention: Intravenous (i.v.) fluids
Number of subjects: 58
Study 10051076 — intervention group
Group type: EXPERIMENTAL
Intervention: High PEEP (15 cm H2O) with conventional I:E ratio (1:2)
Number of subjects: 23
Study 10051076 — intervention group
Group type: EXPERIMENTAL
Intervention: Inverse I:E ratio (2:1) with low PEEP (5 cm H2O)
Number of subjects: 23
Study 10051076 — intervention group
Group type: EXPERIMENTAL
Intervention: Low PEEP (5 cm H2O) with conventional I:E ratio (1:2)
Number of subjects: 23
Study 10051076 — intervention group
Group type: COMPARATOR
Intervention: High PEEP or IRV
Number of subjects: 23
Study 10051076 — intervention group
Group type: EXPERIMENTAL
Intervention: A‐aDO2 and PaO2/PAO2
Number of subjects: 23
Study 7473116 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior chamber fluid from phacoemulsification surgery
Number of subjects: 103
Study 7473116 — intervention group
Group type: COMPARATOR
Intervention: Sterile balanced salt solution (control)
Number of subjects: 103
Study 1693033 — intervention group
Group type: EXPERIMENTAL
Intervention: Environment-sensitive episodes in unipolar depressed patients
Number of subjects: 0
Study 1693033 — intervention group
Group type: EXPERIMENTAL
Intervention: Autonomous episodes in bipolar depressed patients
Number of subjects: 0
Study 1693033 — intervention group
Group type: EXPERIMENTAL
Intervention: Environment-sensitive episodes in bipolar depressed patients
Number of subjects: 0
Study 1693033 — intervention group
Group type: EXPERIMENTAL
Intervention: Environment-sensitive episodes in manic subjects
Number of subjects: 0
Study 1693033 — intervention group
Group type: EXPERIMENTAL
Intervention: Autonomous episodes in manic subjects
Number of subjects: 0
Study 7004214 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine hydrochloride (WR 142,490)
Number of subjects: 0
Study 7004214 — intervention group
Group type: COMPARATOR
Intervention: Sulfadoxine‐pyrimethamine
Number of subjects: 0
Study 29275638 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor imagery
Number of subjects: 20
Study 29275638 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 20
Study 28364461 — intervention group
Group type: EXPERIMENTAL
Intervention: Armodafinil (150-250 mg)
Number of subjects: 28
Study 28364461 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 27053145 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal pressure ulcer-preventative care group (treatment) - regular turning every 2 hours with at least 15 minutes of tissue decompression.
Number of subjects: 1812
Study 27053145 — intervention group
Group type: COMPARATOR
Intervention: Standard care group (control) - no specific intervention details provided.
Number of subjects: 1812